Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uproleselan - GlycoMimetics

Drug Profile

Uproleselan - GlycoMimetics

Alternative Names: GMI-1271; Uproleselan sodium - GlycoMimetics

Latest Information Update: 16 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlycoMimetics
  • Developer GlycoMimetics; National Cancer Institute (USA)
  • Class Antineoplastics; Antithrombotics; Glycolipids; Small molecules
  • Mechanism of Action E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Deep vein thrombosis
  • No development reported Chronic myeloid leukaemia; Multiple myeloma; Solid tumours; Stem cell mobilisation

Most Recent Events

  • 06 Nov 2019 Updated efficacy data from a phase I/II trial in Acute myeloid leukaemia released by GlycoMimetics
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Multiple-myeloma(Adjunctive treatment, Second-line therapy or greater) in Ireland (IV)
  • 01 Aug 2019 GlycoMimetics and National Cancer Institute initiates enrolment in a phase III trial in Acute myeloid leukaemia (Newly diagnosed)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top